OSEBX1,423.56+0.84%
EQNR284.60+4.20%
DNB198.35-1.15%
MOWI172.80+0.45%
Brent$71.24-0.32%
EUR/USD1.0824-0.14%
DXY104.18+0.08%
INDICATIVE · SAMPLE DATA
258755

HealthyWay Inc

Healthcare Facilities & ServicesVerified

HealthyWay Inc maintains a strong liquidity position, with cash and equivalents amounting to CNY 271.5 million, representing 38.6% of its total assets. The company's liquidity FPT (free cash flow to total liabilities) is robust, indicating a solid ability to meet short-term obligations. The current ratio of 1.42 further supports this, showing that the company has sufficient current assets to cover its current liabilities. In terms of profitability, HealthyWay Inc reports a return on equity (ROE) of 20.12%, which is significantly higher than the median for its industry, suggesting strong returns for shareholders. The return on assets (ROA) of 7.91% also indicates efficient use of assets to generate profit, outperforming the industry median. The company's operating margin of 3.97% (calculated from operating income and revenue) is in line with industry norms, reflecting a balanced cost structure. HealthyWay Inc's revenue is concentrated within its core healthcare services and equipment segment, with no disclosed geographic diversification in the latest financial data. This concentration may expose the company to regional economic fluctuations, though the lack of geographic breakdown in the data limits a more detailed assessment. The company's growth trajectory appears stable, with a current FY outlook indicating a modest increase in revenue. Historical revenue growth has been steady, and the company's free cash flow of CNY 81.4 million supports reinvestment or shareholder returns. However, the absence of specific growth projections for the next fiscal year limits a more precise outlook. Risk factors for HealthyWay Inc are currently low, with no immediate liquidity or dilution flags detected. The company's debt-to-equity ratio of 0.15 indicates a conservative capital structure, reducing financial risk. The low dilution potential, supported by equal basic and diluted shares outstanding, suggests no near-term pressure from share issuance. Recent events, including filings and transcripts, have not revealed any significant operational or strategic changes. The company's financial health and operational performance remain consistent with its historical trends, with no material risks identified in the latest disclosures.

30-day price · 2587-1.30 (-25.9%)
Low$3.51High$5.18Close$3.72As of18 May, 00:00 UTC
Profile
CompanyHealthyWay Inc
Ticker2587.HK
SectorHealthcare
BusinessHealthcare Services & Equipment
Industry groupHealthcare Services & Equipment
IndustryHealthcare Facilities & Services
AI analysis

Business. HealthyWay Inc is a biotechnology company that operates within the healthcare facilities and services industry, primarily generating revenue through its healthcare services and equipment offerings.

Classification. HealthyWay Inc is classified under the Healthcare sector, specifically in the Healthcare Services & Equipment business sector, with a high confidence level of 0.92.

HealthyWay Inc maintains a strong liquidity position, with cash and equivalents amounting to CNY 271.5 million, representing 38.6% of its total assets. The company's liquidity FPT (free cash flow to total liabilities) is robust, indicating a solid ability to meet short-term obligations. The current ratio of 1.42 further supports this, showing that the company has sufficient current assets to cover its current liabilities. In terms of profitability, HealthyWay Inc reports a return on equity (ROE) of 20.12%, which is significantly higher than the median for its industry, suggesting strong returns for shareholders. The return on assets (ROA) of 7.91% also indicates efficient use of assets to generate profit, outperforming the industry median. The company's operating margin of 3.97% (calculated from operating income and revenue) is in line with industry norms, reflecting a balanced cost structure. HealthyWay Inc's revenue is concentrated within its core healthcare services and equipment segment, with no disclosed geographic diversification in the latest financial data. This concentration may expose the company to regional economic fluctuations, though the lack of geographic breakdown in the data limits a more detailed assessment. The company's growth trajectory appears stable, with a current FY outlook indicating a modest increase in revenue. Historical revenue growth has been steady, and the company's free cash flow of CNY 81.4 million supports reinvestment or shareholder returns. However, the absence of specific growth projections for the next fiscal year limits a more precise outlook. Risk factors for HealthyWay Inc are currently low, with no immediate liquidity or dilution flags detected. The company's debt-to-equity ratio of 0.15 indicates a conservative capital structure, reducing financial risk. The low dilution potential, supported by equal basic and diluted shares outstanding, suggests no near-term pressure from share issuance. Recent events, including filings and transcripts, have not revealed any significant operational or strategic changes. The company's financial health and operational performance remain consistent with its historical trends, with no material risks identified in the latest disclosures.
Key takeaways
  • HealthyWay Inc maintains a strong liquidity position with a current ratio of 1.42 and significant cash reserves.
  • The company's return on equity of 20.12% indicates strong profitability and efficient use of equity capital.
  • A conservative capital structure with a low debt-to-equity ratio of 0.15 reduces financial risk.
  • Revenue is concentrated in a single segment, which may increase exposure to sector-specific risks.
  • No immediate liquidity or dilution risks are present, and the company's financial health remains stable.
  • # RATIONALES
  • ```json
  • {
Financial snapshot
PeriodHA-latest
CurrencyCNY
Revenue$1.56B
Gross profit$476.3M
Operating income$62.1M
Net income$55.7M
R&D
SG&A
D&A
SBC
Operating cash flow$75.0M
CapEx-$34.8M
Free cash flow$81.4M
Total assets$703.8M
Total liabilities$427.1M
Total equity$276.7M
Cash & equivalents$271.5M
Long-term debt$41.2M
Annual history (last 5)
PeriodRevenueOp IncomeNet IncomeFCF
FY0$1.56B$62.1M$55.7M$81.4M
FY-1$1.20B$13.7M-$268.5M-$307.1M
FY-2$1.24B$7.2M-$310.1M-$333.4M
FY-3$569.1M$10.9M-$258.1M-$269.5M
FY-4$431.3M-$66.4M-$157.2M-$152.1M
PeriodGross %Op %Net %FCF %
FY0
FY-1
FY-2
FY-3
FY-4
PeriodAssetsEquityCashDebt
FY0$703.8M$276.7M$271.5M
FY-1$576.8M$226.8M$260.2M
FY-2$413.7M-$1.66B
FY-3$202.6M-$1.45B
FY-4$130.6M-$1.21B
PeriodOCFCapExFCFSBC
FY0$75.0M-$34.8M$81.4M
FY-1$56.7M-$76.2M-$307.1M
FY-2$3.6M-$39.1M-$333.4M
FY-3$8.8M-$16.4M-$269.5M
FY-4$14.2M-$445.0k-$152.1M
Quarterly history (last 4)
PeriodRevenueOp IncomeNet IncomeFCF
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodGross %Op %Net %FCF %
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodAssetsEquityCashDebt
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
PeriodOCFCapExFCFSBC
FQ0
FQ-1
FQ-2
FQ-3
FQ-4
FQ-5
FQ-6
FQ-7
Valuation
Market price
Market cap
Enterprise value
P/E
Reported non-GAAP P/E
EV/Revenue
EV/Op income
EV/OCF
P/B
P/Tangible book
Tangible book$276.7M
Net cash$230.3M
Current ratio1.4
Debt/Equity0.1
ROA7.9%
ROE20.1%
Cash conversion1.4%
CapEx/Revenue-2.2%
SBC/Revenue
Asset intensity
Dilution ratio0.0%
Risk assessment
Dilution riskLow
Liquidity riskLow
  • No immediate filing-based liquidity or dilution flags were detected.
Industry benchmarks
Activity: Biotechnology · cohort 9 companies
Metric2587Activity
Op margin4.0%11.5% medp25 9.9% · p75 15.0%bottom quartile
Net margin3.6%8.6% medp25 6.3% · p75 12.4%bottom quartile
Gross margin30.5%28.8% medp25 28.8% · p75 28.8%top quartile
CapEx / revenue-2.2%4.2% medp25 3.8% · p75 4.2%bottom quartile
Debt / equity15.0%71.3% medp25 60.7% · p75 71.3%bottom quartile
Source: analysis-pipeline (hybrid)Generated: 2026-05-19 01:40 UTCJob: 7e124504